• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics

    1/7/25 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    • Get Treated with CoolSculpting® Elite and Enter for a Chance to Win $10,000*
    • Starting Today, First-Time Users Can Claim $300 Off Their Treatment†

    IRVINE, Calif., Jan. 7, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced its third annual CoolMonth featuring CoolSculpting® Elite. The celebration is an opportunity for consumers interested in body contouring to reach out to a CoolSculpting® Elite expert and discuss their body contouring treatment options. CoolSculpting® is the number one non-surgical fat reduction treatment providers use most.1

    "We know self-care resolutions are particularly top of mind this time of year," says Carrie Strom, President Allergan Aesthetics and SVP AbbVie. "That's why, we're excited to kick off CoolMonth earlier than ever before by offering two promotions starting in January to help people jumpstart 2025 and reach their goals."

    Follow these steps to unlock exclusive CoolMonth offers:

    • Join Allē, the Allergan Aesthetics Loyalty Program: If you're not already a member, visit the Allē website to register for free and take advantage of offers year-round.



    • Redeem the CoolMonth First-Time Patient Promotion: New patients can claim $300 off a CoolSculpting® treatment starting today through February 6, 2025 (while supplies last). See if you are eligible for the limited-time CoolMonth offer at https://alle.com/offer/coolsculpting-300off-acq2025. Patients have 45 days from the date they claim their offer to redeem the promotion.†



    • Register for the CoolMonth Sweepstakes: All patients who register for the sweepstakes on https://alle.com/sweeps/coolmonth today through February 6, book a consultation and get treated with CoolSculpting® treatment by March 24, 2025, will be entered for a chance to win $10,000.*

    "I typically see more patients come in to discuss non-invasive body contouring treatments as the holiday season winds down. It's a great time to talk about their options and map out a treatment plan because it will allow for patients to see their desired results in time for spring and summer," says Michelle M. Welch R.N. at Coolspa by Aethos and Clinical Training Manager for Allergan Medical Institute. "I call CoolSculpting® the 'finishing touch' because it helps treat stubborn pockets of fat that are resistant to diet and exercise, leaving patients with a more sculpted appearance."

    Like CoolSculpting®, CoolSculpting® Elite is FDA-cleared for the treatment of visible fat bulges in the thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm in patients with a Body Mass Index (BMI) of ≤ 30 and in submental and submandibular areas in patients with a BMI of ≤ 46.2.

    To learn more about CoolSculpting® Elite, the CoolMonth offerings and to find a provider near you, please visit www.CoolSculpting.com. 

    *NO PURCHASE NECESSARY. Open to Allē Members in 50 U.S./D.C.; 18+ (19+ in AL, NE; 21+ in MS). You must register online at https://alle.com/sweeps/coolmonth between 12:00:01 AM PT on 1/7/25 and 11:59:59 PM PT on 2/6/25. Treatment must occur by 3/24/25. See full Official Rules for all details and how to enter without purchase at https://alle.com/lp/coolmonth-official-rules.

    †Offers are limited time only and while supplies last. Terms and Conditions apply. Limited member eligibility applies.

    CoolSculpting® and CoolSculpting® Elite Consumer Important Safety Information

    Uses

    CoolSculpting® and CoolSculpting® Elite are FDA-cleared for the treatment of visible fat bulges in the submental (under the chin) and submandibular (under the jawline) areas, thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments. CoolSculpting® and CoolSculpting® Elite are not treatments for weight loss.

    Important Safety Information

    This procedure is not for everyone. You should not be treated with CoolSculpting® or CoolSculpting® Elite if you suffer from cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.

    Tell your doctor if you are pregnant or have any medical conditions including recent surgery, pre-existing hernia, and any known sensitivities or allergies.

    During the procedure you may experience sensations of pulling, tugging, mild pinching, intense cold, tingling, stinging, aching, cramping and discomfort at the treatment site. These sensations lessen as the area becomes numb. Following the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, stinging, tenderness, cramping, skin inflammation and aching. Sensory alteration (itching, skin sensitivity, tingling, and numbness) can persist up to several weeks after treatment. You may also experience throat discomfort/soreness and sensation of fullness in the back of the throat after submental or submandibular area treatment.

    Rare side effects may happen in 1 to 10 out of 10,000 CoolSculpting® and CoolSculpting® Elite treatments (between 0.01% to 0.1%). One such rare side effect is a visible enlargement in the treated area, which may develop 2 to 5 months after treatment, will not resolve on its own, and may require surgical intervention for correction.

    Please see full Important Safety Information for CoolSculpting® and CoolSculpting® Elite on CoolSculpting.com.

    REFERENCE:

    1. Data on file, Allergan, 2024; Portfolio Aesthetic Monthly Tracker; February 2024 Data Month.

    © 2025 AbbVie. All rights reserved. COOLSCULPTING, COOLSCULPTING ELITE and the Snowflake Design are trademarks of Zeltiq Aesthetics, Inc., an AbbVie company. Allē and its design are service marks of Allergan, Inc., an AbbVie company.

    Allergan Aesthetics (PRNewsfoto/AbbVie)

     

    CoolMonth Logo

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/coolmonth-is-back-with-deals-on-coolsculpting-elite-by-allergan-aesthetics-302343303.html

    SOURCE AbbVie

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    2/20/2026$275.00Overweight
    Barclays
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    1/7/2026$240.00Neutral
    UBS
    12/10/2025$265.00Hold → Buy
    HSBC Securities
    11/13/2025$280.00Sector Outperform
    Scotiabank
    11/4/2025$237.00Buy → Hold
    DZ Bank
    10/14/2025Buy → Hold
    Erste Group
    More analyst ratings

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Controller Purdue David Ryan sold $1,221,519 worth of shares (5,230 units at $233.56), decreasing direct ownership by 66% to 2,654 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    3/6/26 5:05:44 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CHIEF HR OFFICER Crum Demetris D covered exercise/tax liability with 1,594 shares, decreasing direct ownership by 17% to 7,914 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    3/6/26 5:02:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, R&D and CSO Thakkar Roopal covered exercise/tax liability with 8,037 shares, decreasing direct ownership by 13% to 52,376 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    3/3/26 6:14:39 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on AbbVie with a new price target

    RBC Capital Mkts initiated coverage of AbbVie with a rating of Outperform and set a new price target of $260.00

    2/25/26 7:48:26 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on AbbVie with a new price target

    Barclays initiated coverage of AbbVie with a rating of Overweight and set a new price target of $275.00

    2/20/26 8:23:14 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie downgraded by Wolfe Research

    Wolfe Research downgraded AbbVie from Outperform to Peer Perform

    1/8/26 8:35:39 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

    ABBV-295 treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 (weekly dosing), to -7.86% to -9.73% at week 13 (every other week and monthly dosing after week 5)1ABBV-295 demonstrated a favorable tolerability profile at all evaluated dose levels.  No serious adverse events were reported1Data support continued development of ABBV-295 as a potentially differentiated treatment for chronic weight management, with a non-incretin-based mechanism of action NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluati

    3/9/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS

    Data shows a rise in specific treatment demand; a shift in patient consultation and the rising role of facial volume restoration 67% of patients say MWL treatment changed their goals toward improving appearance, not just weight reductioni.Nearly half of MWL patients (47%) were reported by HCPs to benefit most from hyaluronic acid injectable fillers when addressing post-weight-loss facial concernsii.60% of consumers receiving GLP-1 medications obtain them from providers who also offer aesthetic treatments, up from 49% in late 2024iii.IRVINE, Calif., March 4, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, shares new data illustrating how the rapid adoption of Medical Weight Loss

    3/4/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Present at the Leerink Partners Global Healthcare Conference

    NORTH CHICAGO, Ill., March 3, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will participate in a fireside chat at 10:20 a.m. Central Time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therape

    3/3/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    SEC Filings

    View All

    SEC Form PRE 14A filed by AbbVie Inc.

    PRE 14A - AbbVie Inc. (0001551152) (Filer)

    3/9/26 4:31:02 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    3/4/26 4:59:47 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    2/26/26 5:14:40 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    View All

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    Financials

    Live finance-specific insights

    View All

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

    Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer

    2/4/26 7:48:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

    NORTH CHICAGO, Ill., Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key t

    1/7/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    1/25/24 4:59:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/9/23 10:54:46 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care